The tweet was deleted by the author.
But we saved everything 🙂.
Castle Biosciences has unveiled AdvanceAD-Tx, a genetic testing platform that evaluates the expression of 487 genes across 12 separate inflammatory and cutaneous biology pathways.
This tool provides clinicians with one of two actionable molecular profiles—a JAK Inhibitor Responder Profile or a Th2 Molecular Profile—aiming to help medical professionals better understand the underlying immune mechanisms in patients and enhance personalized treatment strategies.
View post on X Loading...
Castle Biosciences’ introduction of AdvanceAD-Tx highlights a broader commitment to precision medicine, building upon prior research demonstrating the company’s i31-SLNB test's sentinel lymph node prediction accuracy in melanoma, as explored in recent coverage. These advancements align with findings that the DecisionDx-Melanoma i31-SLNB platform can identify patients below the 5 percent NCCN threshold for sentinel lymph node biopsy, signaling the firm's sustained focus on expanding molecular diagnostics to refine treatment pathways.